TICKERNERD
Menu
OTLKOTLKHealthcare · Biotechnology

OTLK Stock Forecast: Outlook Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$0.66
−0.15% on the day

The 4 Wall Street analysts covering Outlook Therapeutics, Inc. hold a median 12-month price target of $4 — +506.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 4 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$160.2M
Ticker Nerd rank
4 / 100
Median analyst target
$4.00
Analysts covering
4
Revenue$9K−99.4% y/y
Operating income−$10.8M
Net income−$20.3M
Free cash flow−$21.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.7%
1M
−41.6%
YTD
−58.2%
1Y
−39.4%
From 52W high
−73.3%
From 52W low
+233.3%
$0.20
$2.47
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OTLK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Outlook Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
4 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
70
Revisions
56
Momentum
21
Volatility
17
Growth
8
Accruals
8
Value
5
Quality
4
Issuance
1

Size (70): Smaller than most of the companies we track.

Issuance (1): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OTLK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OTLK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26OTLKHigh $10.50Median $4.00Low $1.60

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
3 Buy1 Hold0 Sell
Low $1.60Median $4.00High $10.50

The green dot is the last close — the median target sits +506.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026BTIGReiteratesBuy$4.00
27 July 2026BTIGUpgradeBuy—
27 July 2026BTIGUpgradeBuy$4.00
27 July 2026HC Wainwright & Co.MaintainsNeutral—
27 July 2026HC Wainwright & Co.MaintainsNeutral$0.50 → $1.60
11 June 2026Ascendiant CapitalMaintainsBuy$6.00 → $10
11 June 2026Ascendiant CapitalMaintainsBuy—
18 May 2026BTIGDowngradeNeutral—
11 Mar 2026Ascendiant CapitalMaintainsBuy—
18 Feb 2026Chardan CapitalMaintainsNeutral—
18 Feb 2026HC Wainwright & Co.ReiteratesNeutral—
5 Jan 2026Chardan CapitalMaintainsNeutral—
2 Jan 2026HC Wainwright & Co.MaintainsNeutral—
22 Dec 2025Ascendiant CapitalMaintainsBuy—
30 Sept 2025HC Wainwright & Co.ReiteratesNeutral—
22 Sept 2025Ascendiant CapitalMaintainsBuy—
29 Aug 2025GuggenheimDowngradeNeutral—
29 Aug 2025HC Wainwright & Co.DowngradeNeutral—
28 Aug 2025Chardan CapitalMaintainsNeutral—
15 Aug 2025Chardan CapitalMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OTLK appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

OTLK vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Outlook Therapeutics, Inc. returned −39.4% against +17.5% for the S&P 500, dividends included.

OTLK vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150200Oct 25Jan 26Apr 26Jul 26OTLKS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OTLK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Outlook Therapeutics, Inc. (OTLK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.6×

Cheaper than 71% of US stocks

Price / sales
−138.1×

Cheaper than 99% of US stocks

Price / book
−8.7×

Cheaper than 97% of US stocks

EV / EBITDA
−3.0×

Cheaper than 75% of US stocks

Growth & margins
Revenue growth (YoY)
−99.4%

Higher than 2% of US stocks

Earnings growth (YoY)
−99.4%

Higher than 2% of US stocks

Gross margin
−95.0%

Higher than 1% of US stocks

Operating margin
−124255.3%

Higher than 1% of US stocks

Net margin
4.0%

Higher than 58% of US stocks

Returns & dividend
Return on equity
193.9%

Higher than 98% of US stocks

Return on assets
−143.2%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Outlook Therapeutics, Inc. (OTLK) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Outlook Therapeutics, Inc. has a market value of $160.2M and an enterprise value of $167.9M.

  • Revenue in the twelve months to 30 June 2026: −$1.2M. The latest quarter shrank 99.4% year on year.

  • Net income over the same four quarters: −$61.1M, a 5253.5% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$56.2M.

  • Shares outstanding: 187.0M.

  • Trailing P/E: 0.6×; forward P/E: −5.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Outlook Therapeutics, Inc. employs 17 people — −$68K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

OTLK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
OTLKOutlook Therapeutics, Inc.$160.2M
4
CNTNCanton Strategic Holdings, Inc.$162.7M
13
CDXSCodexis, Inc.$157.6M
64
IMUXImmunic, Inc.$155.6M
34
SPRBSpruce Biosciences, Inc.$154.3M
27
MDWDMediWound Ltd.$168.1M
26
HUMAHumacyte, Inc.$153.0M
17

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Outlook Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OTLK news & analysis

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

GlobeNewsWire · 11 Sept 2026neutral

Outlook Therapeutics announced that a fireside chat featuring CEO Bob Jahr, conducted at the H.C. Wainwright conference, is now available on-demand. The conversation was hosted by an H.C. Wainwright managing director and senior biotechnology equity research analyst.

Why it matters — OTLK watchers can access the executive discussion for insight into the company's positioning as presented at a major investment conference.

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

GlobeNewsWire · 10 Sept 2026positive

Outlook Therapeutics CEO Bob Jahr participated in a Virtual Investor CEO Connect segment to discuss the FDA approval of LYTENAVA and its commercial opportunity. The release directs readers to access the segment online.

Why it matters — An OTLK watcher would care because the segment focuses on LYTENAVA's FDA approval and commercial opportunity, which are central to the company's near-term outlook.

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

GlobeNewsWire · 27 Aug 2026positive

Outlook Therapeutics announced the appointment of Kevin Lundquist as Chief Financial Officer. Lundquist brings more than 20 years of leadership experience across global commercial organizations in the pharmaceutical and medical technology industries, with expertise in commercial operations, capital markets, public company finance, and building scalable financial and operational infrastructure.

Why it matters — The appointment comes as Outlook Therapeutics prepares for the U.S. commercial launch of LYTENAVA, adding a seasoned finance executive to support that upcoming milestone.

OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp

Zacks Investment Research · 17 Aug 2026neutral

In its Q3 earnings call, Outlook Therapeutics outlined its U.S. LYTENAVA launch plan, targeting a year-end 2026 launch with $50M-$75M in first-year net revenues. The company tied the expected sales ramp to reimbursement dynamics.

Why it matters — For an OTLK watcher, this provides the company's own timing and revenue expectations for the LYTENAVA U.S. commercial launch, a key near-term catalyst for the stock.

FAQ

Frequently asked questions about OTLK stock

What is the OTLK stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Outlook Therapeutics, Inc. have a median 12-month price target of $4, with estimates ranging from $1.6 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OTLK stock a buy right now?

Of the 4 analysts covering Outlook Therapeutics, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Outlook Therapeutics, Inc. 4 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OTLK?

As at 12 Sept 2026, Outlook Therapeutics, Inc. ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (70 of 100).

Will OTLK stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +506.1% from the last close, and Ticker Nerd's factor model ranks Outlook Therapeutics, Inc. 4 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OTLK stock forecast for 2030?

No analyst covering Outlook Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OTLK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.6 to $11 over the next 12 months.

How has OTLK stock performed over the past year?

Outlook Therapeutics, Inc. returned -39.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Outlook Therapeutics, Inc. do?

Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology and retinal diseases.

What is the latest news on OTLK?

The most recent item we track (GlobeNewsWire, 11 Sept 2026): "Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand". Outlook Therapeutics announced that a fireside chat featuring CEO Bob Jahr, conducted at the H.C. Wainwright conference, is now available on-demand. The conversation was hosted by an H.C. Wainwright managing director and senior biotechnology equity research analyst.

Company

About Outlook Therapeutics, Inc.

Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology and retinal diseases. The company develops and commercializes LYTENAVA (bevacizumab-vikg, bevacizumab gamma), an ophthalmic formulation of bevacizumab designed for use in retinal indications such as wet age-related macular degeneration. Its product work centers on ONS-5010, a monoclonal antibody candidate intended to address unmet needs in the treatment of retinal vascular disorders. Outlook Therapeutics operates in the specialty eye-care segment of the pharmaceutical market, where biologic therapies are used to support vision-related conditions affecting the retina. The company’s current business is built around advancing and commercializing this ophthalmic anti-VEGF therapy across regulated markets for patients with serious retinal diseases.

CEO Mr. Robert Charles Jahr · 17 employees · United States · https://outlooktherapeutics.com